NewAmsterdam Pharma Company (NAMS) Stock Forecast & Price Target

Compare

207 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NAMS Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

NewAmsterdam

Pharma Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NAMS Stock 12 Month Forecast

Average Price Target

$39.60

▲(53.73% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for NewAmsterdam Pharma Company in the last 3 months. The average price target is $39.60 with a high forecast of $52.00 and a low forecast of $23.60. The average price target represents a 53.73% change from the last price of $25.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","34":"$34","53":"$53","24.5":"$24.5","43.5":"$43.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,24.5,34,43.5,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,23.643076923076926,26.006153846153847,28.369230769230768,30.732307692307693,33.09538461538462,35.458461538461535,37.82153846153846,40.184615384615384,42.54769230769231,44.91076923076923,47.27384615384615,49.636923076923075,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,22.68923076923077,24.09846153846154,25.50769230769231,26.916923076923077,28.326153846153847,29.735384615384618,31.144615384615385,32.55384615384615,33.963076923076926,35.37230769230769,36.78153846153846,38.190769230769234,{"y":39.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,21.45846153846154,21.63692307692308,21.815384615384616,21.993846153846157,22.172307692307694,22.35076923076923,22.52923076923077,22.70769230769231,22.886153846153846,23.064615384615387,23.243076923076924,23.421538461538464,{"y":23.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$52.00

Average Price Target$39.60

Lowest Price Target$23.60

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen Rahimi

Piper Sandler

$37

Buy

43.63%

Upside

Reiterated

08/11/25

Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

Dex Genotek

TR | OpenAI - 4o

$24→$27

Hold

4.81%

Upside

Reiterated

08/09/25

AI Generated ArticleAI Generated Article

George Farmer

Scotiabank

$52

Buy

101.86%

Upside

Reiterated

08/07/25

Scotiabank Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

Roanna Ruiz

Leerink Partners

$45→$44

Buy

70.81%

Upside

Reiterated

08/07/25

Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data

Serge Belanger

Needham

$40

Buy

55.28%

Upside

Reiterated

08/06/25

Promising Developments and Strong Financial Position Support Buy Rating for NewAmsterdam Pharma

Leonid Timashev

RBC Capital

$38→$39

Buy

51.40%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Surgery Partners (NASDAQ: SGRY)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/06/25

Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Cardiometabolic Drug Developments

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/06/25

Buy Rating for NewAmsterdam Pharma Driven by Promising Trial Developments and Strategic Advancements

Steven Seedhouse

Cantor Fitzgerald

$42

Buy

63.04%

Upside

Reiterated

07/30/25

Cantor Fitzgerald Remains a Buy on NewAmsterdam Pharma Company (NAMS)

Asad Haider

Goldman Sachs

$23.6

Hold

-8.39%

Downside

Initiated

07/17/25

NewAmsterdam Pharma initiated with a Neutral at Goldman SachsNewAmsterdam Pharma initiated with a Neutral at Goldman Sachs

Geoff Meacham

Citi

$42

Buy

63.04%

Upside

Initiated

06/18/25

NewAmsterdam Pharma initiated with a Buy at CitiNewAmsterdam Pharma initiated with a Buy at Citi

James Condulis

Stifel Nicolaus

$44

Buy

70.81%

Upside

Initiated

06/12/25

NewAmsterdam Pharma initiated with a Buy at StifelNewAmsterdam Pharma initiated with a Buy at Stifel

Dennis Ding

Jefferies

$45

Buy

74.69%

Upside

Reiterated

06/11/25

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer's Opportunities

Debjit Chattopadhyay

Guggenheim

$35→$41

Buy

59.16%

Upside

Reiterated

03/03/25

NewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimNewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim

Ed Arce

H.C. Wainwright

$48

Buy

86.34%

Upside

Reiterated

01/14/25

Promising Outlook for NewAmsterdam Pharma: Ed Arce's Buy Rating Backed by Strategic Developments and Phase 3 SuccessesWe employ a risk-adjusted NPV (rNPV) valuation model to estimate the value of NAMS shares, and arrive at our $48 PT based on: (1) about $29 per share for U.S. net sales and EU royalties on obicetrapib in secondary ASCVD prevention (assume commercial launch in 1H27; 85% PoS; $4.7B global peak revenues in 2042); and (2) about $19 per share as a placeholder value for obicetrapib in primary ASCVD prevention (about 40% larger opportunity than secondary prevention; 40% PoS). In our valuation model, we employ a 12.0% discount rate, which we believe adequately reflects the overall risks facing NewAmsterdam.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen Rahimi

Piper Sandler

$37

Buy

43.63%

Upside

Reiterated

08/11/25

Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

Dex Genotek

TR | OpenAI - 4o

$24→$27

Hold

4.81%

Upside

Reiterated

08/09/25

AI Generated ArticleAI Generated Article

George Farmer

Scotiabank

$52

Buy

101.86%

Upside

Reiterated

08/07/25

Scotiabank Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

Roanna Ruiz

Leerink Partners

$45→$44

Buy

70.81%

Upside

Reiterated

08/07/25

Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data

Serge Belanger

Needham

$40

Buy

55.28%

Upside

Reiterated

08/06/25

Promising Developments and Strong Financial Position Support Buy Rating for NewAmsterdam Pharma

Leonid Timashev

RBC Capital

$38→$39

Buy

51.40%

Upside

Reiterated

08/06/25

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Surgery Partners (NASDAQ: SGRY)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/06/25

Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Cardiometabolic Drug Developments

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/06/25

Buy Rating for NewAmsterdam Pharma Driven by Promising Trial Developments and Strategic Advancements

Steven Seedhouse

Cantor Fitzgerald

$42

Buy

63.04%

Upside

Reiterated

07/30/25

Cantor Fitzgerald Remains a Buy on NewAmsterdam Pharma Company (NAMS)

Asad Haider

Goldman Sachs

$23.6

Hold

-8.39%

Downside

Initiated

07/17/25

NewAmsterdam Pharma initiated with a Neutral at Goldman SachsNewAmsterdam Pharma initiated with a Neutral at Goldman Sachs

Geoff Meacham

Citi

$42

Buy

63.04%

Upside

Initiated

06/18/25

NewAmsterdam Pharma initiated with a Buy at CitiNewAmsterdam Pharma initiated with a Buy at Citi

James Condulis

Stifel Nicolaus

$44

Buy

70.81%

Upside

Initiated

06/12/25

NewAmsterdam Pharma initiated with a Buy at StifelNewAmsterdam Pharma initiated with a Buy at Stifel

Dennis Ding

Jefferies

$45

Buy

74.69%

Upside

Reiterated

06/11/25

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer's Opportunities

Debjit Chattopadhyay

Guggenheim

$35→$41

Buy

59.16%

Upside

Reiterated

03/03/25

NewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimNewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim

Ed Arce

H.C. Wainwright

$48

Buy

86.34%

Upside

Reiterated

01/14/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NewAmsterdam Pharma Company

1 Month

xxx

Success Rate

7/9 ratings generated profit

Average Return

+10.36%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 77.78% of your transactions generating a profit, with an average return of +10.36% per trade.

3 Months

xxx

Success Rate

7/9 ratings generated profit

Average Return

+15.33%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +15.33% per trade.

1 Year

Serge BelangerNeedham

Success Rate

9/9 ratings generated profit

Average Return

+26.70%

reiterated a buy rating 9 days ago

Copying Serge Belanger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.70% per trade.

2 Years

xxx

Success Rate

9/9 ratings generated profit

Average Return

+26.70%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +26.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NAMS Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NAMS has received 25 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. NAMS average Analyst price target in the past 3 months is 39.60.

Each month's total comprises the sum of three months' worth of ratings.

NAMS Financial Forecast

NAMS Earnings Forecast

Next quarter’s earnings estimate for NAMS is -$0.40 with a range of -$0.51 to -$0.27. The previous quarter’s EPS was -$0.15. NAMS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.29% of the time in the same period. In the last calendar year NAMS has Outperformed its overall industry.

NAMS Sales Forecast

Next quarter’s sales forecast for NAMS is $5.31M with a range of $0.00 to $29.74M. The previous quarter’s sales results were $19.14M. NAMS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.71% of the time in the same period. In the last calendar year NAMS has Outperformed its overall industry.

NAMS Stock Forecast FAQ

What is NAMS’s average 12-month price target, according to analysts?

Based on analyst ratings, NewAmsterdam Pharma Company’s 12-month average price target is 39.60.

What is NAMS’s upside potential, based on the analysts’ average price target?

NewAmsterdam Pharma Company has 53.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NAMS a Buy, Sell or Hold?

NewAmsterdam Pharma Company has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is NewAmsterdam Pharma Company’s price target?

The average price target for NewAmsterdam Pharma Company is 39.60. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $23.60. The average price target represents 53.73% Increase from the current price of $25.76.

What do analysts say about NewAmsterdam Pharma Company?

NewAmsterdam Pharma Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of NAMS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

NewAmsterdam Pharma Company (NAMS) Stock Forecast & Price Target

NAMS Analyst Ratings

NAMS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NewAmsterdam Pharma Company

NAMS Analyst Recommendation Trends

NAMS Financial Forecast

NAMS Earnings Forecast

NAMS Sales Forecast

NAMS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts